Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

WELLS, Maine — Wells High School has announced its first trimester honor roll for the 2024-25 school year.

Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...

The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...